SCHEMBL13130686

SCHEMBL13130686

CC(C)O/N=C1\COc2ccccc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
KMT2A Q03164 2/20 0.35
MIF P14174 1/20 0.35
TSHR P16473 3/20 0.34
PKM P14618 1/20 0.34
MAOB P27338 5/20 0.34
ALDH1A1 P00352 6/20 0.33
KDM4E B2RXH2 4/20 0.33
GAA P10253 3/20 0.33
HPGD P15428 3/20 0.33
PIK3CA P42336 2/20 0.33
ATM Q13315 2/20 0.33
GLA P06280 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPC1 O15118 1/20 0.33
ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13130689 0.84 MEN1 (0.37) MAPTKMT2ATSHRPKMPIK3CA
SCHEMBL6653939 0.81 MIF (0.40) MAPTKMT2AMIFTSHRPKM
SCHEMBL18924655 0.81 MIF (0.40) MAPTKMT2AMIFTSHRPKM
SCHEMBL6656648 0.81 MIF (0.40) MAPTKMT2AMIFTSHRPKM
SCHEMBL16378822 0.74 ALDH1A1 (0.41) KMT2AMIFTSHRPKMMAOB
SCHEMBL16378813 0.74 ALDH1A1 (0.41) KMT2AMIFTSHRPKMMAOB
SCHEMBL12609455 0.74 ALDH1A1 (0.44) MAPTKMT2AMIFTSHRPKM
SCHEMBL14879150 0.73 KDM4E (0.36) MAPTKMT2AMIFTSHRPKM
SCHEMBL13130682 0.72 SMN1; SMN2 (0.43) MAPTKMT2AALDH1A1GAAHPGD
SCHEMBL1266177 0.71 RAD52 (0.46) MAPTKMT2AMIFTSHRPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563732-B2 Oxyimino compounds and the use thereof SHIONOGI & CO., LTD. (JP) 2013-10-22 US disclosed
US-20100240703-A1 OXYIMINO COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240703-A1 OXYIMINO COMPOUNDS AND THE USE THEREOF CACNA1A, CACNA1S, OPRM1 MAPT 3109/4885KMT2A 2355/4885MIF 3533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.